Compare · DYN vs RGNX
DYN vs RGNX
Side-by-side comparison of Dyne Therapeutics Inc. (DYN) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. DYN focuses on Biotechnology: Pharmaceutical Preparations, while RGNX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- DYN is the larger of the two at $3.00B, about 6.3x RGNX ($478.7M).
- DYN has been more active in the news (12 items in the past 4 weeks vs 10 for RGNX).
- Both have 24 recent analyst ratings on file.
- Company
- Dyne Therapeutics Inc.
- REGENXBIO Inc.
- Price
- -
- -
- Market cap
- $3.00B
- $478.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 12
- 10
- Recent ratings
- 24
- 24
Dyne Therapeutics Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest DYN
- Chief Commercial Officer Friedl-Naderer Johanna sold $3,885 worth of shares (231 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 152,666 units (SEC Form 4) to cover taxes
- Head of R&D and CMO Kerr Douglas sold $43,799 worth of shares (2,604 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 167,960 units (SEC Form 4) (for tax liability)
- CEO & President Cox John sold $92,729 worth of shares (5,513 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 351,994 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Lucera Erick sold $33,489 worth of shares (1,991 units at $16.82) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 117,775 units (SEC Form 4) (withholding tax)
- SEC Form SCHEDULE 13G filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- SEC Form 144 filed by Dyne Therapeutics Inc.
- Dyne Therapeutics to Participate in Upcoming Investor Conference
- Dyne Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest RGNX
- SEC Form SCHEDULE 13G filed by REGENXBIO Inc.
- SEC Form 10-Q filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
- Chief Technology Officer Malzahn Craig was granted 27,777 shares, increasing direct ownership by 34% to 109,737 units (SEC Form 4)
- Chief Strategy & Legal Officer Christmas Patrick J. was granted 34,722 shares, increasing direct ownership by 17% to 240,690 units (SEC Form 4)
- Chief Medical Officer Pakola Steve was granted 34,722 shares, increasing direct ownership by 17% to 240,263 units (SEC Form 4)
- Chief Financial Officer Chan Mitchell was granted 24,305 shares, increasing direct ownership by 20% to 147,120 units (SEC Form 4)
- REGENXBIO to Participate in Stifel 2026 Healthcare Conference
- REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights